Evotec SE ADR (EVO)
NASDAQ: EVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EVO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $469.11M
- EPS (TTM)
- -$0.59
- Dividend yield
- None
- 52-week range
- 1.32 – 3.87
- Day range
- 1.32 – 1.38
- Volume / Avg
- 77.59K / 109.16K
- Beta
- —
- Shares outstanding
- 355.39M
52-week range
EVO stock today
Evotec (EVO) closed at $1.32 on Nov 20, down 8.97% (-$0.13), versus the S&P 500's 3.70% decline. At this level, EVO sits near the bottom of its 52-week range of $1.32 to $3.87: 65.9% below the high, set on Jan 13, 2026 and 0.0% above the low. EVO is down 57.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.6%.
Evotec has posted a net loss over the last twelve months (EPS of -$0.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Evotec
Company profileEvotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Christian Wojczewski Ph.D.
- Headquarters
- Hamburg
- Employees
- 4,379
- IPO year
- 2021
- Website
- evotec.com
Analyst forecast
ForecastConsensus (3 analysts)
buy
Avg. price target
$4.45+237.12%
- Strong buy 1
- Buy 1
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
EVO news
All EVO news- Evotec & Bristol Myers Squibb Get IND Clearance For Second Molecular Glue CandidateNasdaqBMY, EVO
- Evotech & Bristol Myers Squibb Get IND Clearance For Second Molecular Glue CandidateNasdaqBMY, EVO
- Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND AcceptancePR Newswire
- Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026PR Newswire
- Evotec Appoints Former Novo Nordisk Executive Joanna Holbrook As Chief Scientific Officer; Stock UpNasdaqEVO, ET
- Evotec Sees 9-Month Results Above Market; Reiterates FY26 OutlookNasdaq
Evotec peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MNPRMonopar Therapeutics Inc. | 69.00 | -1.84% | $467.60M | vs EVO |
| RZLTRezolute Inc. | 3.92 | -6.67% | $465.58M | vs EVO |
| BLSMBlossomHill Therapeutics Inc. | 14.51 | +0.69% | $461.20M | vs EVO |
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs EVO |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs EVO |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs EVO |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs EVO |
| HELPHelus Pharma Inc. | 6.11 | -9.88% | $487.68M | vs EVO |
Indexes, lists and sector
Evotec stock FAQ
What is Evotec's stock price today?
EVO last traded at $1.32 as of Nov 20, 4:00 PM EST, down 8.97% on the day. Prices are delayed at least 15 minutes.
Does Evotec pay a dividend?
No. Evotec does not currently pay a regular cash dividend.
Who is Evotec's CEO?
Dr. Christian Wojczewski Ph.D. is the chief executive officer of Evotec SE ADR, which has about 4,379 employees.
Has EVO ever split its stock?
Yes. The most recent EVO stock split was a 4-for-1 split on Oct 20, 2021, one of 2 splits on record.
What is the EVO 52-week high?
The 52-week high for EVO is $3.87 and the 52-week low is $1.32. The stock is currently 65.9% below its high.